3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
9
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
Gynecologic
2
Sarcoma
1
NET
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
163
Breast Neoplasms
162
Carcinoma, Non-Small-Cell Lung
60
Melanoma
44
Ovarian Neoplasms
42
Colorectal Neoplasms
37
Carcinoma, Renal Cell
36
Squamous Cell Carcinoma of Head and Neck
33
Pancreatic Neoplasms
29
Stomach Neoplasms
28
Neoplasm Metastasis
27
Uterine Cervical Neoplasms
24
Neoplasms
24
Endometrial Neoplasms
24
Lung Neoplasms
19
Head and Neck Neoplasms
19
Esophageal Neoplasms
18
Carcinoma, Transitional Cell
18
Carcinoma, Hepatocellular
16
Urinary Bladder Neoplasms
14
Small Cell Lung Carcinoma
14
Prostatic Neoplasms
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Sarcoma
10
Mesothelioma
9
Kidney Neoplasms
9
Cholangiocarcinoma
9
Carcinoma, Ovarian Epithelial
9
Carcinoma, Merkel Cell
9
Fallopian Tube Neoplasms
8
Interventions
Docetaxel
7
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Biopsy
3
Vorinostat
2
Trastuzumab
2
Taxes
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Flow Cytometry
2
zanidatamab
1
vandetanib
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
pembrolizumab
1
larotrectinib
1
fluoromisonidazole
1
entrectinib
1
entinostat
1
ceralasertib
1
alectinib
1
X-Ray Therapy
1
Thalidomide
1
Specimen Handling
1
Rubidium-82
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pembrolizumab
×
Breast
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled